dr. marks on investigational antibody-drug conjugates in her2 breast cancer
Published 4 years ago • 279 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:38
dr. hart on antibody-drug conjugates in her2 breast cancer
-
0:57
dr. cobleigh on antibody-drug conjugates in development in her2 breast cancer
-
3:36
her2 breast cancer: evolution of antibody-drug conjugates
-
2:06
antibody-drug conjugates for her2-low disease: 2023 ku breast cancer year in review
-
37:44
clinical perspectives on her2-targeted antibody-drug conjugates: treatment-related adverse events
-
0:52
dr. julie gralow discusses the antibody drug conjugate t-dm1 for breast cancer
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
6:20
antibody-drug conjugates for tnbc
-
10:11
a brief introduction of antibody drug conjugate - creative biolabs
-
27:06
dr. hong's biotechnology lecture 04: cancers and antibody drug conjugate
-
8:32
antibody structure and function tricks | structure and function of antibody mnemonics
-
5:59
use of antibody drug conjugates and potential for ild
-
25:46
antibody drug conjugates present and future applications in breast cancer
-
1:06
dr. edith perez on the antibody-drug conjugate t-dm1
-
1:31
dr. andreadis on antibody-drug conjugates in dlbcl
-
2:02
dr. soliman the utility of adcs in breast cancer
-
1:23
antibody-drug conjugates for the treatment of breast cancer
-
1:10
dr. mei on investigational car t-cell therapies and antibody-drug conjugates in hodgkin lymphoma
-
0:49
optimizing patient selection for antibody drug conjugates in breast cancer
-
2:11
next-generation antibody-drug conjugates in her2 breast cancer
-
1:04
dr. isaacs discusses antibody drug conjugates in tnbc
-
1:08
dr. singh on research with antibody-drug conjugates in advanced bladder cancer